Terrosa 20 micrograms/80 microliters solution for injection in pre-filled pen clinical trials

Prospective, randomized, multicentre study to compare the efficacy at 52 weeks (1 year) of biosimilar teriparatide and alendronate in the prevention of new morphometric vertebral fractures and/or worsening of previous vertebral fractures in women with a clinical vertebral fracture or recent hip fracture (imminent risk of fracture) caused by bone fragility.

This study compares two treatments, Terrosa and alendronate, to see which is better at preventing new or worsening spinal fractures in women who have recently had a fracture. It lasts for one year and checks how many new breaks occur.